The Foundation for Prader-Willi Research (FPWR) is funding nine projects that intend to improve understanding and help find treatments, including gene therapies, for Prader-Willi syndrome (PWS). In total, FPWR awarded a total of $912,251 in the first round of this year’s research awards, according to a press release.
News
This May, the Foundation for Prader-Willi Research (FPWR) is mobilizing people around the world affected by Prader-Willi syndrome (PWS) to raise awareness about the disease and host fundraising activities to advance disease research. This year’s PWS Awareness Month came to be thanks to the efforts of Republican…
FFF Enterprises and Bionews announced today that both rare and orphan disease advocates are joining forces to provide patients with resources to help them connect as a community and continue to manage their health during this time when many are finding themselves alone. Recognized as the nation’s leading supplier of…
While there are few silver linings to the cloud created by COVID-19, the pandemic that has killed tens of thousands, hobbled economies worldwide and drove millions to quarantine in their homes, one may be a new appreciation of telemedicine. “If something good could come out of this crisis, it’s that…
The approach used by diazoxide choline controlled-release (DCCR), Soleno Therapeutics’ investigational oral therapy to reduce appetite in people with Prader-Willi syndrome (PWS), has shown promise in improving insulin sensitivity and reducing body fat in several animal models of obesity linked to excessive eating. The findings were…
The National Organization for Rare Disorders (NORD) has opened a financial assistance program for people in the rare disease community who are affected by the COVID-19 pandemic in the U.S. Called the NORD COVID-19 Critical Relief Program, the effort will provide up to $1,000 annually to those eligible…
Children with Prader-Willi syndrome (PWS) struggle to express adequate facial and bodily emotions, which is linked to difficulties adapting socially, a study suggests. The study, “Equivocal expression of emotions in children with Prader-Willi syndrome: what are the consequences for emotional abilities and social adjustment?,” was published in the…
First, the bad news: If you’re one of the 30 million or so Americans with a rare disease, you probably have lower immunity to the novel coronavirus than most people. Now, the good news: You already know how to face loneliness and adversity — qualities that make you far stronger…
Millendo Therapeutics‘ treatment candidate livoletide failed to significantly reduce hunger and improve food-related behaviors in people with Prader-Willi syndrome (PWS) who are taking part in the pivotal ZEPHYR Phase 2b/3 clinical trial. Also, the treatment did not improve other measures, such as body fat, waist circumference,…
Parents and teachers attribute different severity to behavioral problems of children with Prader–Willi syndrome (PWS), according to a recent study. Although parents see food-related issues, such as repetitive speech and compulsive behavior as being more severe, teachers report that the impact of such problems on daily activities is higher. The study,…
Recent Posts
- First participant dosed in Phase 2a trial of CSTI-500 for Prader-Willi syndrome
- Setmelanotide successfully targeting extreme hunger, obesity in PWS trial
- PWS study disputes growth hormone link to infant sleep apnea
- Summertime with PWS means sun, fun, and structure
- Waist size may flag higher metabolic risk in people with PWS
- Sensory processing issues act as major driver of irritability in PWS
- Heart data prompts FDA to halt trial of Prader-Willi syndrome drug ARD-101
- May brings awareness days, a sweet 16, and a reminder from peonies
- Phase 2 trial of nasal spray for Prader-Willi hunger delayed to 2027
- Infants with PWS show early blood flow changes in key brain regions